Adviser Investments LLC acquired a new stake in shares of Pfizer, Inc. (NYSE:PFE) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 128,618 shares of the biopharmaceutical company’s stock, valued at approximately $4,400,000.
A number of other hedge funds also recently made changes to their positions in the stock. Massmutual Trust Co. FSB ADV bought a new stake in shares of Pfizer during the fourth quarter valued at $8,476,000. Iberiabank Corp increased its stake in shares of Pfizer by 19.0% in the fourth quarter. Iberiabank Corp now owns 161,088 shares of the biopharmaceutical company’s stock valued at $5,232,000 after buying an additional 25,744 shares during the last quarter. Fiduciary Financial Services of The Southwest Inc. TX increased its stake in shares of Pfizer by 0.7% in the fourth quarter. Fiduciary Financial Services of The Southwest Inc. TX now owns 179,556 shares of the biopharmaceutical company’s stock valued at $5,832,000 after buying an additional 1,318 shares during the last quarter. Brown Advisory Inc. increased its stake in shares of Pfizer by 2.4% in the fourth quarter. Brown Advisory Inc. now owns 1,404,712 shares of the biopharmaceutical company’s stock valued at $45,624,000 after buying an additional 32,538 shares during the last quarter. Finally, Sii Investments Inc. WI increased its stake in shares of Pfizer by 12.3% in the fourth quarter. Sii Investments Inc. WI now owns 158,488 shares of the biopharmaceutical company’s stock valued at $5,126,000 after buying an additional 17,303 shares during the last quarter. Hedge funds and other institutional investors own 69.95% of the company’s stock.
Pfizer, Inc. (PFE) opened at 33.48 on Friday. Pfizer, Inc. has a 12-month low of $29.83 and a 12-month high of $37.39. The firm has a 50-day moving average price of $33.20 and a 200-day moving average price of $33.25. The company has a market cap of $199.80 billion, a P/E ratio of 28.18 and a beta of 1.01.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $0.69 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.67 by $0.02. The business had revenue of $12.78 billion during the quarter, compared to analyst estimates of $13.09 billion. Pfizer had a return on equity of 23.68% and a net margin of 13.76%. Pfizer’s revenue was down 1.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.67 EPS. On average, equities research analysts forecast that Pfizer, Inc. will post $2.55 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Friday, August 4th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 3.82%. The ex-dividend date is Wednesday, August 2nd. Pfizer’s dividend payout ratio (DPR) is presently 108.48%.
Several brokerages have weighed in on PFE. Morgan Stanley reiterated a “neutral” rating and issued a $38.00 price objective on shares of Pfizer in a research report on Thursday, April 6th. BidaskClub upgraded Pfizer from a “strong sell” rating to a “sell” rating in a research report on Friday, June 23rd. Jefferies Group LLC reiterated a “neutral” rating and issued a $35.00 price objective (up previously from $34.00) on shares of Pfizer in a research report on Thursday, April 13th. BMO Capital Markets reiterated a “hold” rating and issued a $33.00 price objective on shares of Pfizer in a research report on Thursday, April 27th. Finally, Sanford C. Bernstein reiterated a “buy” rating and issued a $35.00 price objective on shares of Pfizer in a research report on Monday, April 24th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and ten have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $37.68.
About Pfizer
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
